



Patent Docket No. P1219P101

1FW/#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Trade Application of Timothy A. Stewart, et al. Serial No.: 10/715,795 Filed: November 17, 2003 For: FIBROBLAST GROWTH FACTOR-19 (FGF-19) NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE FOR THE TREATMENT OF OBESITY	Group Art Unit: 1646 Examiner: Olga N. Chernyshev Confirmation No: 5748 CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Date: <u>1-24-05</u> By: <u>Pam Golden</u> Pam Golden
---	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

- ☐ 37 CFR §1.97(b) within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or before the mailing of the first Office action on the merits; or before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.
- ☒ 37 CFR §1.97(c) by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.
- ☐ 37 CFR §1.97(d) after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

01/31/2005 AWONDAF1 00000005 070630 10715795

01 FC:1806 #172140.00 DA

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.

☒ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because a) ☒ they were previously cited by or submitted to the Office in a prior application Serial No. 09,522,342 (ABN) filed 03/09/2000 which is a CIP of Serial No. 09/284,663 (ABN), filed 04/15/1999 which is a CON of Serial No. 09/158,342 (ABN), filed 09/21,1998 which claims benefit of Serial No. 60/066,840, filed 11/25/1997 and relied upon in this application for an earlier filing date under 35 USC §120 and/ or because b) ☐ this application was filed after June 30, 2003. Applicants are no longer required to submit copies of U.S. patents and U.S. patent application publications cited in information disclosure statements for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003 (1276 OG 55). Nevertheless, applicants stand ready to provide copies at the request of the Examiner.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-())" (nucleotide) and "BLAST Results B-1 - B-())" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given
- ☐ given for each listed item
- ☐ given for only non-English language listed item(s) [Required]
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,
GENENTECH, INC.

Date: 1/24/05

By: Cara Coburn
Cara M. Coburn
Reg. No. 46,631
Telephone No. (650) 467-6222

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1219P1C1

Serial No.

10/715,795

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Goddard, A. et al.

Filing Date

17 Nov 2003

Group

1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	*73	5,428,130	27.06.95	Capon et al.			
	*74	6,013,477	11.01.00	Greene et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
	75	00/15666		WO				
	76	00/15796		WO				
	77	01/04311 A1		WO				
	78	01/05836 A1		WO				
	79	99/14327		WO				
	80	99/14328		WO				
	81	99/27100		WO				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	*82	Bray, G.A., "Drug Treatment of Obesity." <u>Am. J. Clin. Nutr.</u> 55:538s-544s (1992)						
	*83	Bray, G.A., "Treatment of Obesity: A Nutrient Balance/Nutrient Partition Approach" <u>Nutrition Reviews</u> 49(2):33-45 (1991)						
	84	Evans, G.A. et al., "DATABASE EMBL -EMGSS Entry Hsb7673, Acc. no. B03767 July 16, 1996"						
	*85	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular & Cellular Biology</u> 8:2159-2165 (1988)						
	86	Hillier L., et al., "Database EMBL-EMEST11 Entry Hs1139632, Acc. no. AA220994, February 14, 1997."						
	*87	Jung and Chong., "The Management of Obesity." <u>Clinical Endocrinology</u> . 35:11-20 (1991)						
	*88	Lee et al., "Successful Weight Loss with Protein-Sparing Modified Fast in a Morbidly Obese Boy with Panhypopituitarism, Diabetes Insipidus, and Defective Thirst Regulation" <u>Clin. Pediatr.</u> 31:234-236 (Apr 1992)						
	*89	Palmiter et al., "Dramatic Growth of Mice That Develop From Eggs Microinjected With Metallothionein-Growth Hormone Fusion Genes" <u>Nature</u> 300:611-615 (1982)						
	*90	Rissanen et al., "Risk of Disability and Mortality Due to Overweight in a Finnish Population" <u>Br. Med. J.</u> 301:835-837 (1990)						
	91	Strausbergh R., "Database EMBL- EMEST6 Entry/Acc no. A1076490, 8-10-1998"						
	*92	Weinstein et al., "FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung" <u>Development</u> 125:3615-3623 (1998)						
	*93	Xie et al., "FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4" <u>Cytokine</u> 11(10):729-735 (1999)						

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.